Pacira BioSciences Target of Unusually High Options Trading (NASDAQ:PCRX)

Pacira BioSciences, Inc. (NASDAQ:PCRX) saw some unusual options trading on Wednesday. Investors bought 1,981 call options on the stock. This is an increase of approximately 416% compared to the typical daily volume of 384 call options.

Pacira BioSciences Trading Down 4.7 %

Shares of NASDAQ PCRX opened at $21.66 on Thursday. The company has a debt-to-equity ratio of 0.57, a current ratio of 5.81 and a quick ratio of 4.78. The stock has a market capitalization of $1.01 billion, a P/E ratio of 15.15 and a beta of 0.88. Pacira BioSciences has a 1-year low of $20.52 and a 1-year high of $40.16. The business has a fifty day moving average price of $28.60 and a 200 day moving average price of $29.73.

Pacira BioSciences (NASDAQ:PCRX) last released its quarterly earnings results on Tuesday, May 7th. The company reported $0.42 EPS for the quarter, missing analysts’ consensus estimates of $0.46 by ($0.04). Pacira BioSciences had a net margin of 10.34% and a return on equity of 12.98%. The business had revenue of $167.12 million during the quarter, compared to analysts’ expectations of $165.43 million. Equities research analysts expect that Pacira BioSciences will post 2.13 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on PCRX shares. JPMorgan Chase & Co. started coverage on Pacira BioSciences in a report on Thursday, March 7th. They issued an “overweight” rating and a $45.00 target price for the company. Needham & Company LLC reiterated a “buy” rating and issued a $43.00 target price on shares of Pacira BioSciences in a report on Tuesday. Barclays cut Pacira BioSciences from an “overweight” rating to an “equal weight” rating and lowered their target price for the stock from $38.00 to $25.00 in a report on Wednesday. HC Wainwright restated a “buy” rating and set a $57.00 price objective on shares of Pacira BioSciences in a research note on Tuesday. Finally, Piper Sandler restated an “overweight” rating and set a $42.00 price objective on shares of Pacira BioSciences in a research note on Wednesday. One analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $46.10.

Insider Buying and Selling at Pacira BioSciences

In other Pacira BioSciences news, COO Daryl Gaugler sold 1,000 shares of the company’s stock in a transaction on Thursday, June 13th. The stock was sold at an average price of $28.38, for a total value of $28,380.00. Following the transaction, the chief operating officer now owns 116,040 shares of the company’s stock, valued at approximately $3,293,215.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Pacira BioSciences news, COO Daryl Gaugler sold 1,000 shares of the company’s stock in a transaction on Thursday, June 13th. The stock was sold at an average price of $28.38, for a total value of $28,380.00. Following the transaction, the chief operating officer now owns 116,040 shares of the company’s stock, valued at approximately $3,293,215.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Jonathan Slonin sold 2,836 shares of the company’s stock in a transaction on Tuesday, July 2nd. The stock was sold at an average price of $28.25, for a total value of $80,117.00. Following the completion of the sale, the insider now owns 95,557 shares of the company’s stock, valued at $2,699,485.25. The disclosure for this sale can be found here. Insiders have sold 21,150 shares of company stock valued at $602,170 in the last quarter. 6.40% of the stock is owned by insiders.

Institutional Investors Weigh In On Pacira BioSciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. GAMMA Investing LLC raised its stake in Pacira BioSciences by 229.6% in the second quarter. GAMMA Investing LLC now owns 1,338 shares of the company’s stock valued at $38,000 after buying an additional 932 shares during the last quarter. Park Place Capital Corp purchased a new stake in Pacira BioSciences in the second quarter valued at about $46,000. Jane Street Group LLC raised its stake in Pacira BioSciences by 1,780.2% in the first quarter. Jane Street Group LLC now owns 187,531 shares of the company’s stock valued at $5,480,000 after buying an additional 177,557 shares during the last quarter. Paloma Partners Management Co purchased a new stake in Pacira BioSciences in the first quarter valued at about $209,000. Finally, Archon Capital Management LLC purchased a new stake in Pacira BioSciences in the first quarter valued at about $15,677,000. 99.73% of the stock is currently owned by hedge funds and other institutional investors.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.